Douglas W. Jamison is Chairman, Chief Executive Officer and a Managing Director of Harris & Harris Group, Inc., a publicly traded venture capital company listed on the Nasdaq Global Market. Harris & Harris Group focuses solely in making initial investments in “tiny” technologies, which it defines as nanotechnology and microsystems. He has previously held the positions of President, Chief Operating Officer and Chief Financial Officer of Harris & Harris Group, Inc. He is also currently Chairman and Chief Executive Officer of Harris & Harris Enterprises, Inc., a wholly owned subsidiary of Harris & Harris Group. Mr. Jamison is a Member of the board of directors of Ancora Pharmaceuticals Inc. and a Board Observer in ABSMaterials, Inc.; Mersana Therapeutics; Solazyme, Inc.; Nextreme Thermal Solutions; and Metabolon, Inc., privately held nanotechnology-enabled portfolio companies of Harris & Harris Group. He is Co-Editor in Chief of Nanotechnology Law & Business. He is Co-Chair of the Advisory Board, Converging Technology Bar Association, a Member of the University of Pennsylvania Nano-Bio Interface Ethics Advisory Board, and a Member of the Advisory Board, Massachusetts Technology Collaborative Nanotechnology venture forum. Prior to joining Harris & Harris Group, Mr. Jamison was a Senior Technology Manager at the University of Utah Technology Transfer Office, where he managed intellectual property in physics, chemistry and the engineering sciences. He is a graduate of Dartmouth College (B.A., 1992) and the University of Utah (M.S., 1999).
